Australia markets open in 5 hours

MGC Pharmaceuticals Limited (MXC.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.6750-0.0200 (-2.88%)
At close: 04:10PM AEDT
Full screen
Previous close0.6950
Open0.6950
Bid0.6750 x 125665700
Ask0.6950 x 8008500
Day's range0.6750 - 0.6950
52-week range0.0010 - 2.0000
Volume16,283
Avg. volume2,389,498
Market cap23.916M
Beta (5Y monthly)1.34
PE ratio (TTM)N/A
EPS (TTM)-7.1000
Earnings date26 Feb 2024 - 01 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.04
  • PR Newswire

    Historic Milestone: UK Patients Receive First CannEpil® Delivery through 'I AM Billy Foundation' and GMC Specialist Register

    MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a leading European pharmaceutical firm specializing in plant-derived medications, announced today that its ground-breaking Investigational Medicinal Product (IMP), CannEpil®, has been successfully imported and received by its first patients in the United Kingdom.

  • PR Newswire

    MGC Pharma's CannEpil® Now Accessible to UK Patients on Named Patient Request Basis

    MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based pharmaceutical company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its proprietary product CannEpil® is now available to patients in the UK by Named Patient Request.

  • PR Newswire

    ArtemiC TM Listed as an OTC Drug in the USA; AMC Places US$2m Order

    MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a European based bio-pharma company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its innovative product ArtemiC™ has recently been listed as an over-the-counter (OTC) drug in the USA on the FDA National Drug Code (NDC) Database under the code 83278. Facilitated by the company's US-based supply and distribution partner, AMCPharma USA, LLC. (AMC), ArtemiC™ will be